These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 17333521)

  • 1. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
    Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
    Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
    Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
    Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
    Chu FM; Dmochowski RR; Lama DJ; Anderson RU; Sand PK
    Am J Obstet Gynecol; 2005 Jun; 192(6):1849-54; discussion 1854-5. PubMed ID: 15970828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder.
    Armstrong RB; Luber KM; Peters KM
    Int Urol Nephrol; 2005; 37(2):247-52. PubMed ID: 16142551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.
    Medhi B; Mittal N; Bansal D; Prakash A; Sarangi SC; Nirthi B
    Indian J Physiol Pharmacol; 2013; 57(4):343-53. PubMed ID: 24968572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
    Reinberg Y; Crocker J; Wolpert J; Vandersteen D
    J Urol; 2003 Jan; 169(1):317-9. PubMed ID: 12478180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder.
    Lee JG; Hong JY; Choo MS; Kwon HY; Chung DY; Lee KS; Lee JY; Lee T
    Int J Urol; 2002 May; 9(5):247-52. PubMed ID: 12060436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The newer antimuscarinic drugs: bladder control with less dry mouth.
    Appell RA
    Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolterodine: a clinical review.
    Crandall C
    J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
    Hughes DA; Dubois D
    Pharmacoeconomics; 2004; 22(16):1047-59. PubMed ID: 15524493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review.
    Rovner ES; Wein AJ
    Eur Urol; 2002 Jan; 41(1):6-14. PubMed ID: 11999467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
    Zinner NR; Mattiasson A; Stanton SL
    J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
    Appell RA
    Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
    Abrams P; Freeman R; Anderström C; Mattiasson A
    Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.